🟢 Icecure Medical is trading 8.41% up today after Adventist Health Glendale became first ChoICE site

Icecure Medical is trading 8.41% up now at $3.47 after announcing on August 6, 2026, that Adventist Health Glendale became the first site able to enroll patients in its post-marketing ChoICE study for ProSense breast-cancer treatment.

• The update strengthens the company’s U.S. commercialization and clinical-adoption narrative.
• Healthcare-sector strength and the ongoing rebound may also be supporting sentiment, but the clinical-site announcement is the clearest company-specific catalyst.